# Evrys Bio

Evrys Bio is an Asset Manager based in Doylestown, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Doylestown, United States
- **Region:** North America
- **Address:** Doylestown, PA, United States
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** evrysbio.com
- **LinkedIn:** https://www.linkedin.com/company/forge-life-science

## Regulatory record

- **Reports private funds:** No

## About

Evrys Bio develops antiviral therapeutics in the life sciences sector. The company focuses on broad-spectrum antiviral drugs that enhance the body's immune response to viral infections. Evrys Bio's products target conditions such as hepatitis and respiratory infections, and may provide protection for immunosuppressed patients.

## Sectors

- Biotech
- Healthcare Services

## Offices

- Menlo Park, CA
- Zurich, Switzerland
- Cambridge, MA

## People

- Lillian Chiang — President & CEO

## Questions

### What is Evrys Bio's core scientific approach?

Evrys Bio develops host-targeted antivirals — small molecules that block the human cell proteins viruses require for replication rather than attacking the virus directly. The platform originated from Princeton University research on sirtuins, a class of host proteins that regulate cellular responses to stress and that viruses exploit. By inhibiting these host factors, Evrys aims to create drugs effective against multiple virus families with a higher genetic barrier to resistance than traditional direct-acting antivirals.

### Who founded Evrys Bio and where did the technology originate?

Thomas Shenk and Lillian Chiang founded Evrys Bio in 2014 based on intellectual property licensed from Princeton University. Shenk, a prominent virologist, is the James A. Elkins Jr. Professor in the Life Sciences at Princeton and a past president of the American Society for Virology. Chiang, a Princeton-trained molecular biologist who worked in Shenk's lab, now leads the company as President and CEO.

### What infectious diseases does Evrys Bio target?

Evrys Bio's pipeline targets human cytomegalovirus, respiratory syncytial virus, filoviruses such as Ebola and Marburg, and herpesviruses. Because its mechanism acts on host cell pathways rather than viral proteins, the same underlying technology can be applied to multiple viral families. The firm received a BARDA contract in 2020 to advance filovirus candidates.

### Has Evrys Bio received government funding?

Yes. In 2020, the Biomedical Advanced Research and Development Authority awarded Evrys Bio a contract valued at up to $63 million (over a multi-year period subject to milestones) to support the development of host-targeted antivirals against filoviruses. This non-dilutive funding has been a significant source of research capital for the company.

## Related profiles

- [QVT Funds](https://altss.com/profile/qvt-funds)
- [Juvare](https://altss.com/profile/juvare)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/evrys-bio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology